Ziftomenib
2023-1008
Phase 1 small_molecule active
Quick answer
Ziftomenib for Refractory Acute Leukemia is a Phase 1 program (small_molecule) at Kura Oncology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kura Oncology
- Indication
- Refractory Acute Leukemia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active